IP Library Granted Patent US 8,691,769
Granted Patent B2
US 8,691,769 · App. 10/793,964 · Granted Apr 8, 2014

Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,691,769
App. No.
10/793,964
Granted
Apr 8, 2014
Kind
B2
Abstract

The present invention provides methods for treating sinus-evoked headaches using botulinum toxin injected or applied in multiple subcutaneous locations over divisions of the trigeminal nerve in soft tissues and dermatomes overlying the corresponding effected sinuses implicated in the etiology of the pain.

Claims (32)

1. A method of treating headache and facial pain associated with acute recurrent or chronic sinusitis comprising the steps of selecting a subject suffering from acute recurrent or chronic sinusitis who no longer exhibits sinus inflammation, and administering a therapeutically effective amount of a composition comprising botulinum toxin to the subject's nasal mucosa or to the subcutaneous structures overlying the subject's sinuses; wherein the administration of the composition reduces the headache and facial pain associated with acute recurrent or chronic sinusitis.

2. The method of claim 1 , wherein the sinuses are one or more of the sinuses selected from the group consisting of: ethmoid; maxillary; mastoid; frontal; and sphenoid.

3. The method of claim 2 , wherein the subcutaneous structures overlying the sinuses lie within one or more of the areas selected from the group consisting of forehead; malar; temporal; post auricular; and lip.

4. The method of claim 1 , wherein the subcutaneous structures overlying the sinuses lie within one or more of the areas selected from the group consisting of forehead; malar; temporal; post auricular; and lip.

5. The method of claim 1 , wherein the composition is administered to the nasal mucosa.

6. The method of claim 1 , wherein the composition is administered at a dose between 15 and 200 mouse LD50 units of botulinum toxin.

7. The method of claim 1 , wherein the composition is administered at a dose between 15 and 50,000 mouse LD50 units of botulinum toxin.

8. The method of claim 1 , wherein the botulinum toxin is immunotype A.

9. The method of claim 2 , wherein the botulinum toxin is immunotype A.

10. The method of claim 4 , wherein the botulinum toxin is immunotype A.

11. The method of claim 3 , wherein the botulinum toxin is immunotype A.

12. The method of claim 1 , wherein the composition is administered by injection.

13. The method of claim 12 , wherein there are at least two injection sites.

14. The method of claim 2 , wherein the composition is administered by injection.

15. The method of claim 14 , wherein there are at least two injection sites.

16. The method of claim 4 , wherein the composition is administered by injection.

17. The method of claim 16 , wherein there are at least two injection sites.

18. The method of claim 3 , wherein the composition is administered by injection.

19. The method of claim 18 , wherein there are at least two injection sites.

20. The method of claim 1 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

21. The method of claim 2 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

22. The method of claim 4 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

23. The method of claim 3 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

24. The method of claim 12 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

25. The method of claim 14 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

26. The method of claim 16 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

27. The method of claim 18 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

28. The method of claim 13 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

29. The method of claim 15 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

30. The method of claim 17 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

31. The method of claim 19 , wherein the composition is administered to the projections of the trigeminal nerve innervating the sinus.

32. A method of treating headache and facial pain associated with acute recurrent or chronic sinusitis comprising the steps of selecting a subject suffering from acute recurrent or chronic sinusitis who no longer exhibits sinus inflammation, and administering a therapeutically effective amount of a composition comprising botulinum toxin to a location on or within the head of the subject; wherein the administration of the composition reduces the headache and facial pain associated with acute recurrent or chronic sinusitis.

Assignments (8)
SECURITY INTEREST Recorded Feb 17, 2025
From: REVANCE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 070239/0739 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
SECURITY INTEREST Recorded Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2016
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 038870/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2004
From: BORODIC, GARY E.; ACQUADRO, MARTIN ANDREW
To: BOTULINUM TOXIN RESEARCH ASSOCATES, INC.
Reel/Frame 014798/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2004
From: BORODIC, GARY E.; ACQUADRO, MARTIN
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 015182/0270 →